Amyloidosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Amyloidosis – Pipeline Review, H1 2020’, provides an overview of the Amyloidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Amyloidosis

– The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects

– The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Amyloidosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Amyloidosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ADRx Inc

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Auven Therapeutics Development Switzerland Sarl

Bristol-Myers Squibb Co

BSIM Therapeutics SA

Caelum Biosciences Inc

Chugai Pharmaceutical Co Ltd

Corino Therapeutics Inc

Covalent Bioscience Inc

Ebelle Pharmaceuticals Inc

Eidos Therapeutics Inc

Johnson & Johnson

Mabpharm Ltd

Neurimmune Holding AG

Oncopeptides AB

Pfizer Inc

Precision Biosciences Inc

Proclara Biosciences Inc

Prothena Corp Plc

R Pharm

Regeneron Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

TheraPharm Deutschland GmbH

Trucode Gene Repair Inc

Table of Contents

Table of Contents

Introduction

Amyloidosis - Overview

Amyloidosis - Therapeutics Development

Amyloidosis - Therapeutics Assessment

Amyloidosis - Companies Involved in Therapeutics Development

Amyloidosis - Drug Profiles

Amyloidosis - Dormant Projects

Amyloidosis - Discontinued Products

Amyloidosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Amyloidosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Amyloidosis – Pipeline by ADRx Inc, H1 2020

Amyloidosis – Pipeline by Akcea Therapeutics Inc, H1 2020

Amyloidosis – Pipeline by Alnylam Pharmaceuticals Inc, H1 2020

Amyloidosis – Pipeline by Amgen Inc, H1 2020

Amyloidosis – Pipeline by Auven Therapeutics Development Switzerland Sarl, H1 2020

Amyloidosis – Pipeline by Bristol-Myers Squibb Co, H1 2020

Amyloidosis – Pipeline by BSIM Therapeutics SA, H1 2020

Amyloidosis – Pipeline by Caelum Biosciences Inc, H1 2020

Amyloidosis – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020

Amyloidosis – Pipeline by Corino Therapeutics Inc, H1 2020

Amyloidosis – Pipeline by Covalent Bioscience Inc, H1 2020

Amyloidosis – Pipeline by Ebelle Pharmaceuticals Inc, H1 2020

Amyloidosis – Pipeline by Eidos Therapeutics Inc, H1 2020

Amyloidosis – Pipeline by Johnson & Johnson, H1 2020

Amyloidosis – Pipeline by Mabpharm Ltd, H1 2020

Amyloidosis – Pipeline by Neurimmune Holding AG, H1 2020

Amyloidosis – Pipeline by Oncopeptides AB, H1 2020

Amyloidosis – Pipeline by Pfizer Inc, H1 2020

Amyloidosis – Pipeline by Precision Biosciences Inc, H1 2020

Amyloidosis – Pipeline by Proclara Biosciences Inc, H1 2020

Amyloidosis – Pipeline by Prothena Corp Plc, H1 2020

Amyloidosis – Pipeline by R Pharm, H1 2020

Amyloidosis – Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Amyloidosis – Pipeline by Spectrum Pharmaceuticals Inc, H1 2020

Amyloidosis – Pipeline by TheraPharm Deutschland GmbH, H1 2020

Amyloidosis – Pipeline by Trucode Gene Repair Inc, H1 2020

Amyloidosis – Dormant Projects, H1 2020

Amyloidosis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Amyloidosis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Amyloidosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports